These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38452312)

  • 1. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
    Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
    JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
    Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
    JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma.
    Muthusamy B; Raskina K; Lofgren KT; Li G; Tolba K; Schwed K; Castellanos E; Huang RSP; Oxnard GR; Schrock AB; Pennell N
    J Thorac Oncol; 2023 Apr; 18(4):476-486. PubMed ID: 36494074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
    Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
    Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
    Huang RSP; Carbone DP; Li G; Schrock A; Graf RP; Zhang L; Murugesan K; Ross JS; Tolba K; Sands J; Oxnard GR; Spigel D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Stricker T; Jain N; Ma E; Yu E; Wang R; Schuldt R; Price R; Szado T; Sussell J; Ogale S; Lin V; Arrowsmith E; Slater D; Vaena D; Staszewski H; Fang B; Seneviratne L; Daniel D
    Oncologist; 2024 Jun; 29(6):534-542. PubMed ID: 38417095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
    Nadler E; Vasudevan A; Wang Y; Ogale S
    Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.
    Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D
    Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
    Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
    John A; Shah RA; Wong WB; Schneider CE; Alexander M
    Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
    Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
    Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
    Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
    Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
    Harvey MJ; Cunningham R; Sawchyn B; Montesion M; Reddy P; McBride A; Chawla AJ
    JCO Precis Oncol; 2021 Nov; 5():1611-1624. PubMed ID: 34994647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
    Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
    BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
    Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment.
    Russo A; Lee JK; Pasquina LW; Del Re M; Dilks HH; Murugesan K; Madison RW; Lee Y; Schrock AB; Comment L; Dietrich M; Oxnard GR; Rolfo C
    JCO Precis Oncol; 2024 Jan; 8():e2300535. PubMed ID: 38295321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.